PRAGUE, Czech Republic, Nov. 8 /PRNewswire/ -- S*BIO Pte Ltd, today announced the presentation of data on their lead histone deacetylase inhibitor, SB939, during the scientific sessions at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Presented by S*BIO’s Head of Biology, Dr. Jeanette Wood, the two presentations of the data demonstrate that SB939 is a novel compound with superior pharmaceutical, metabolic and pharmacokinetic properties. It has superior oral bioavailability in mice (34%) compared to other competitors in the clinic (<10%), such as Zolinza, PXD101, and LBH589. SB939 has demonstrated excellent in vivo anti-tumour activity in various animal models with dose proportional pharmacodynamic effects. The pharmacokinetics and pharmacodynamic attributes of SB939 explain and differentiate it as the best in class HDAC inhibitor.
“We are pleased with the pharmacological and pharmacokinetic profile of our lead histone deacetylase inhibitor, SB939,” said Jan-Anders Karlsson, CEO of S*BIO. “The data demonstrate that SB939 is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors. We expect to enter clinical trials for SB939 in the first quarter of 2007.”
Abstracts: Poster No. 166 ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor
In S*BIO’s HDAC program, in silico, in vitro and in vivo ADME (Absorption, Distribution, Metabolism and Elimination) studies are incorporated in the screening cascade with a view to discovering compounds with optimal ADME properties. These ADME results provide insight to the medicinal chemists in the lead optimization process and led to the identification of SB939 as a promising drug candidate. In a preclinical tumor model, the superior pharmacokinetics of SB939 correlated well with both a pharmacodynamic marker (H-3 acetylation) as well as anti-tumor efficacy.
Poster No. 162
Pharmacological profile of SB939, a novel, potent and orally active histone deacetylase inhibitor
SB939 is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that SB939 is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
About S*BIO Pte Ltd
S*BIO is a privately held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO intends to become a leading fully integrated oncology-focused biotech company in Asia Pacific.
S*BIO has developed a state-of-the-art R&D infrastructure and expertise to support its efforts in oncology. In anticipation of delivering its first IND in 2006, S*BIO is building a strong clinical development team and is actively fostering close ties with medical oncology networks in Asia Pacific. The Company is aggressively building a pipeline of internal and in-licensed compounds.
More information about S*BIO can be found at www.sbio.com S*BIO Pte Ltd: Noonan Russo: Stephen Keith Rhind, Ph.D. Tony Russo +1 212-845-4251 Senior Vice President, Corporate Development Tony.Russo@eurorscg.com Tel: +65 6827 5000 (Singapore) Andreas Marathovouniotis Stephen_rhind@sbio.com +1 212-845-4253 Andreas.Marathis@eurorscg.com
S*BIO Pte Ltd
CONTACT: Stephen Keith Rhind, Ph.D., Senior Vice President, CorporateDevelopment, S*BIO Pte Ltd, +65-6827-5000, Singapore,Stephen_rhind@sbio.com; or Tony Russo, +1-212-845-4251,Tony.Russo@eurorscg.com, or Andreas Marathovouniotis, +1-212-845-4253,Andreas.Marathis@eurorscg.com, both of Noonan Russo
Web site: http://www.sbio.com/
